Qtr, 2 Aug. 2020
All right. Thank you. And then just
as we are on the topic of international. I would like to see if you could just
give a general update on Lymphoseek in Europe. I know you guys are expecting to
get that back in, I think, November now. So have there been any ongoing
discussions on that front with partners or anything like that?
So we are in the process of, well,
first off, we actually just got back the MA. So we do have the marketing
authorization. So we actually re-own the product now fully. It will continue
until November in terms of the negotiations and extricating ourselves from the
agreement with Norgine and then the discussions will start in earnest once we
have completed. So we are working on a pretty extensive third-party report on
the overall value of the market.
So this is something that we did
sort of initially way back when. But now as the product has gotten more and
more developed, at least in the U.S., we had a third-party do a valuation
report and that will be available in the next week. And then we are going to
turn our attention to the discussion. So we have already had initial calls with
several potential partners. But we expect that to get going in earnest
probably, I would say, the September, October time frame, just because Europe,
August is, even with COVID, August is usually the time off. So I don't expect
much work to get done in Europe in August.